Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1960 1
1962 1
1964 2
1965 2
1966 3
1967 4
1968 2
1969 3
1970 2
1971 4
1972 4
1973 2
1974 5
1975 2
1976 2
1977 5
1978 6
1979 10
1980 1
1981 11
1982 9
1983 9
1984 12
1985 4
1986 12
1987 15
1988 27
1989 24
1990 25
1991 26
1992 22
1993 21
1994 26
1995 36
1996 17
1997 27
1998 33
1999 25
2000 34
2001 38
2002 46
2003 37
2004 49
2005 66
2006 38
2007 55
2008 40
2009 56
2010 51
2011 48
2012 66
2013 65
2014 60
2015 52
2016 42
2017 51
2018 70
2019 50
2020 60
2021 65
2022 55
2023 39
2024 36
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,575 results

Results by year

Filters applied: . Clear all
Page 1
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Among authors: inaba m. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: inaba m. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: inaba m. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Fetuin-A: a multifunctional protein.
Mori K, Emoto M, Inaba M. Mori K, et al. Among authors: inaba m. Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):124-46. doi: 10.2174/187221411799015372. Recent Pat Endocr Metab Immune Drug Discov. 2011. PMID: 22074587 Review.
An introduction to CKD-MBD research: restart for the future.
Fukagawa M, Inaba M, Yokoyama K, Shigematsu T, Ando R, Miyamoto KI; For Japan CKD-MBD Forum. Fukagawa M, et al. Among authors: inaba m. Clin Exp Nephrol. 2017 Mar;21(Suppl 1):1-3. doi: 10.1007/s10157-016-1372-7. Clin Exp Nephrol. 2017. PMID: 28083765 No abstract available.
[Calcitonin, procalcitonin].
Nagasaki T, Inaba M. Nagasaki T, et al. Among authors: inaba m. Nihon Rinsho. 2005 Aug;63 Suppl 8:295-9. Nihon Rinsho. 2005. PMID: 16149513 Review. Japanese. No abstract available.
1,575 results